In this patient’s case, acquired mutations in KRAS with oncogenic potential and NF1 with unknown actionability were observed after prolonged exposure to BRAF inhibition along with a morphological transformation to gliosarcoma. This evidence concerns the gene BRAF and gliosarcoma.